• 1
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 2
    O'Dell JR. Anticytokine therapy: A new era in the treatment of rheumatoid arthritis? N Engl J Med 1999; 340: 3102.
  • 3
    Bathon J, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 4
    Kavanaugh A, Cohen S, Cush J. Inhibitors of tumor necrosis factor (TNF) in rheumatoid arthritis: will that dog hunt? J Rheumatol 1998; 25: 204953.
  • 5
    Pincus T, Wolfe F, Callahan LF. Updating a reassessment of traditional paradigms concerning rheumatoid arthritis. In: WolfeF, PincusT, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment. New York: Marcel Dekker. 1994 174.
  • 6
    Pincus T, Breedveld FC, Emery P. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 1999; 17 suppl 18: S27.
  • 7
    Koch A, Kunkel S, Strieter R. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43: 2838.
  • 8
    Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397440.
  • 9
    Kirkham B, Portek I, Lee CS, Stavros B, Lenarczyk A, Lassere M, et al. Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 77784.
  • 10
    Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75: 30610.
  • 11
    Williams RD, Mauri C, Mason LJ, Marinova-Mutafchieva L, Ross S, Feldmann M, et al. Therapeutic actions of cyclosporine and anti-tumor necrosis factor α in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum 1998; 41: 180612.
  • 12
    Lipsky P, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology 1999; 38 suppl 2: 414.
  • 13
    Benoist C, Mathis D. The pathogen connection. Nature 1998; 394: 2278.
  • 14
    Joosten L, Helsen M, Saxne T, van de Loo F, Heinegard D, van den Berg W. IL-1α/β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999; 163: 504955.
  • 15
    Feige U, Hu Y-L, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000; 57: 145770.
  • 16
    Bendele AM, Chilpala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 264859.
  • 17
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196204.
  • 18
    St Clair EW. Interleukin 10 treatment for rheumatoid arthritis. Ann Rheum Dis 1999; 58: ( Suppl I) I99I103.
  • 19
    Kim K-N, Watanabe S, Ma Y, Thornton S, Giannini EH, Hirsch R. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. J Immunol 2000; 164: 157681.
  • 20
    Van Roon JAG, Lafeber PJG, Bijlsma JWJ. Synergisitc activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44: 312.
  • 21
    Butler DM, Malfait A-M, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen induced arthritis. Eur J Immunol 1999; 29: 220512.
  • 22
    Marinova-Mutafchieva L, Williams RO, Mauri C, Mason LJ, Walmsley MJ, Taylor PC, et al. A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumor necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum 2000; 43: 63844.
  • 23
    Furst D, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999; 58: ( suppl 1) I12930.
  • 24
    Hermann J, Hall M, Maini RN, Feldmann M, Brennan F. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41: 138897.
  • 25
    Ozaki H, Ishii K, Horiuchi H, Arai H, Kawamoto T, Okawa K, et al. Cutting edge: combined treatment of TNF-α and IFN-γ causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol 1999; 163: 5537.
  • 26
    Mattey DL, Hassell AB, Dawes PT, Ollier WE, Hajeer A. Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: influence on disease outcome. Arthritis Rheum 1999; 42: 2698704.
  • 27
    Takasaki W, Kajino Y, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nature Biotechnol 1997; 15: 126670.